TABLE 4.
Predictors of Favorable Clinical Outcome for CS and Non-CS DAVFs
| CS DAVFs (n = 20) | Non-CS DAVFs (n = 111) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Favorable clinical outcomeb | Univariable | Multivariable | Favorable clinical outcomeb | Univariable | Multivariable | |||||||
| Variables | Yes (n = 9) | No (n = 11) | OR (95% CI) | P value | OR (95% CI) | P value | Yes (n = 41) | No (n = 70) | OR (95% CI) | P value | OR (95% CI) | P value |
| Maximum dose >45 Gy, n (%) | 7 (78%) | 2 (18%) | 15.750 (1.754-141.404) | .014 | – | – | 11 (27%) | 18 (25%) | 1.059 (0.422-2.539) | .897 | – | – |
| Margin dose, mean Gy (SD) | 23(5.5) | 21(3.1) | 1.092 (0.865-1.378) | .460 | – | – | 21 (2.6) | 21 (3.2) | 0.985 (0.863-1.124) | .821 | – | – |
| Symptomatic improvement, n (%) | 5 (56%) | 11(100%) | - | .026 a | – | – | 32(78%) | 35(49%) | 3.657 (1.106-12.093) | .034 | 3.428 (0.998-11.783) | .050 |
| Radiological follow-up mean mo (SD) | 29 (10.3) | 31 (22.2) | 0.994 (0.943-1.047) | .812 | – | – | 36 (31.0) | 32 (35.4) | 1.010 (0.998-1.022) | .098 | 0.985 (0.962-1.008) | .196 |
| Clinical follow-up mean mo (SD) | 29 (10.3) | 31 (22.2) | 0.994 (0.943-1.047) | .812 | – | – | 39 (39.9) | 36 (38.9) | 1.014 (1.003-1.024) | .010 | 1.021 (1.000-1.043) | .050 |
CS = cavernous sinus; DAVFs = dural arteriovenous fistulas; OR = odds ratio; CI = confidence interval; n = number; SD = standard deviation; mo = months.
aFisher's exact test.
bFavorable clinical outcome: defined as DAVFs obliteration confirmed on digital subtraction angiography (DSA) without radiological radiation-induced changes (RIC) or post- stereotactic radiosurgery hemorrhage and follow-up ≥12 mo.
Only factors with P < .15 in the univariable analysis were listed in the multivariable analysis.
Boldface type indicates statistical significance.